Castle Biosciences CSTL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$14.52M-523% | -$2.33M-365% | -$501K-111% | $4.52M+117% | -$25.85M-370% | ||
| $3.93M+4.0% | $3.78M-1.0% | $3.82M+11.8% | $3.41M-88.5% | $29.76M+416% | ||
| $9.78M-14.3% | $11.41M-5.7% | $12.1M+8.0% | $11.21M+0.3% | $11.18M-2.3% | ||
| -$10K+98.9% | -$907K— | $0+100% | -$4.67M-506% | -$770K— | ||
| -$1.08M+82.9% | -$6.27M-228% | -$1.91M+51.1% | -$3.91M-175% | $5.22M+578% | ||
| $207K-87.1% | $1.6M+422% | $307K-79.8% | $1.52M+218% | -$1.29M-182% | ||
| $3.19M— | $0-100% | $1.41M+30.9% | $1.07M+74.6% | $615K+208% | ||
| -$19.18M-394% | $6.52M— | —— | —— | -$14.7M-401% | ||
| $6.67M— | —— | —— | $1.33M-60.4% | $3.36M— | ||
| -$532K— | —— | -$63K+66.7% | -$189K-530% | -$30K+50.0% | ||
| $2.02M— | —— | $3.56M+201% | $1.19M+183% | -$1.43M-357% | ||
| -$172K+17.7% | -$209K-6.1% | -$197K+42.6% | -$343K+34.8% | -$526K-23.5% | ||
| -$22.13M-182% | $26.93M+19.0% | $22.63M+8.7% | $20.82M+445% | -$6.04M-125% | ||
| $12.46M+73.4% | $7.18M-51.6% | $14.83M+60.1% | $9.26M+95.4% | $4.74M-37.4% | ||
| $55.14M+47.4% | $37.41M-36.0% | $58.47M+31.7% | $44.4M-8.3% | $48.43M+2.3% | ||
| $2.68M— | —— | —— | —— | $0— | ||
| $7K+40.0% | $5K-73.7% | $19K+58.3% | $12K+33.3% | $9K+28.6% | ||
| $0— | —— | —— | —— | $5.57M— | ||
| —— | $528.5K0.0% | $528.5K0.0% | $528.5K0.0% | $528.5K— | ||
| -$25.8M— | —— | -$18.39M+35.2% | -$28.38M-26.5% | -$22.43M— | ||
| $322K-84.6% | $2.09M+2,617% | $77K+305% | $19K+5.6% | $18K-95.2% | ||
| $24K-11.1% | $27K-12.9% | $31K0.0% | $31K+19.2% | $26K0.0% | ||
| $6.6M-10.5% | $7.37M+522% | $1.19M+101% | $589K-76.6% | $2.52M-60.6% | ||
| -$5.03M-9.7% | -$4.59M-399% | -$919K— | $0+100% | -$1.55M— | ||
| -$52.97M— | —— | —— | -$7.46M+75.2% | -$30.02M-221% | ||
| $454K-35.9% | $708K-21.8% | $905K-22.7% | $1.17M-18.4% | $1.44M-11.0% | ||
| $2.02M— | —— | —— | —— | -$1.43M-1,127% | ||
| -$19.18M-394% | $6.52M— | —— | —— | -$14.7M-401% | ||
| -$172K+17.7% | -$209K-6.1% | -$197K+42.6% | -$343K+34.8% | -$526K-23.5% | ||
| -$371K-4.2% | -$356K-1.1% | -$352K-44.3% | -$244K+41.9% | -$420K-31.3% | ||
| $2.76M— | —— | $1.43M— | —— | $1.14M— | ||
| $530K+69.9% | $312K+661% | $41K— | $0-100% | $38K+113% | ||
| $6.67M— | —— | —— | $1.33M-60.4% | $3.36M— | ||
| -$532K— | —— | -$63K+66.7% | -$189K-530% | -$30K+50.0% | ||
| $0— | —— | —— | —— | $5.57M— | ||
| $2.68M— | —— | —— | —— | $0— | ||
| $7K+40.0% | $5K-73.7% | $19K+58.3% | $12K+33.3% | $9K+28.6% | ||
| $24K-11.1% | $27K-12.9% | $31K0.0% | $31K+19.2% | $26K0.0% | ||
| $1.27M+77.5% | $714K+225% | $220K-57.0% | $512K-47.2% | $970K+49.9% | ||
| $4.1M-40.5% | $6.89M— | —— | $3.61M+12.1% | $3.22M+387% | ||
| -$172K+17.7% | -$209K-6.1% | -$197K+42.6% | -$343K+34.8% | -$526K-23.5% | ||
| $0— | —— | —— | $75K+70.5% | $44K-15.4% | ||
| -$34.58M-275% | $19.75M+153% | $7.8M-32.5% | $11.56M+207% | -$10.78M-164% | ||
| -$34.58M-275% | $19.75M+153% | $7.8M-32.5% | $11.56M+207% | -$10.78M-164% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Castle Biosciences generate?
- Castle Biosciences (CSTL) generated $48.3M in operating cash flow over the trailing twelve months.
- What is Castle Biosciences's free cash flow?
- After $43.7M of capital expenditures, Castle Biosciences's free cash flow was $4.5M over the trailing twelve months, down 89.2% year over year.
- Where does Castle Biosciences's cash flow data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
